← Back to Search

CAR T-cell Therapy

Treatment Arm A for Lymphoma (CASEY Trial)

Phase 1

Waitlist Available

Led By Bilal Omer, MD

Research Sponsored by Baylor College of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up time frame 4 weeks post infusion

Awards & highlights

CASEY Trial Summary

This trial is for patients with lymph gland diseases like Hodgkin or non-Hodgkin Lymphoma. The study focuses on using special infection-fighting blood cells called T cells to target cancer cells

Who is the study for?

This trial is for patients with certain lymph gland diseases, including Hodgkin or non-Hodgkin Lymphoma, T/NK-lymphoproliferative disease, who have not responded well to existing treatments. It's particularly aimed at those whose cancer cells show signs of the Epstein Barr virus (EBV), which is linked to these conditions.Check my eligibility

What is being tested?

The study tests a new gene therapy using modified T cells that target EBV-infected tumor cells. These T cells are engineered with a C7R gene to help them survive longer and potentially improve their ability to fight the cancer. The goal is to determine the safest high dose and its effectiveness against the cancer.See study design

What are the potential side effects?

While specific side effects aren't listed here, similar therapies can cause immune reactions, flu-like symptoms, fatigue, fever, and in some cases more severe complications related to how the body responds to genetically modified T-cells.

CASEY Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ time frame 4 weeks post infusion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~time frame 4 weeks post infusion

This trial's timeline: 3 weeks for screening, Varies for treatment, and time frame 4 weeks post infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose limiting toxicity (DLT) rate

Secondary outcome measures

Overall Response Rate

CASEY Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment Arm AExperimental Treatment1 Intervention

Patients will initially be consented for procurement of blood for generation of the transduced T-cells. Three dose levels will be evaluated and a possible dose level -1 in case of unexpected toxicity at dose level 1. Each patient will receive one T cell infusion.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Baylor College of MedicineLead Sponsor

1,001 Previous Clinical Trials

6,002,240 Total Patients Enrolled

36 Trials studying Lymphoma

1,055 Patients Enrolled for Lymphoma

Bilal Omer, MDPrincipal InvestigatorBaylor College of Medicine

7 Previous Clinical Trials

304 Total Patients Enrolled

1 Trials studying Lymphoma

44 Patients Enrolled for Lymphoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are patients currently able to enroll in this ongoing study?

"According to the details provided on clinicaltrials.gov, recruitment for this particular research project is presently closed. The study was initially listed on 4/1/2024 and last revised on 3/28/2024. Despite this trial no longer accepting participants, there are a vast number of 2872 other studies actively seeking candidates at present."

Answered by AI

What is the risk level associated with Treatment Group A for individuals?

"Our team at Power has rated the safety of Treatment Arm A as 1 on a scale from 1 to 3. This determination is based on it being a Phase 1 trial with restricted data backing its safety and effectiveness."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY)

Bilal Omer 2024. "CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06345027.

All > Acute Myeloid Leukemia > Aml